光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-052 光正眼科医院集团股份有限公司 关于第六届董事会第五次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）第六届董事会第五次 会议于 2025 年 8 月 19 日（星期二）在公司会议室以现场结合通讯方式召开，与 会董事均已知悉与所议事项相关的必要信息。本次会议应出席董事 9 人，实际出 席董事 9 人，公司部分监事及高级管理人员列席了会议。本次会议由董事长周永 麟先生主持，会议的召集、召开程序及参加表决的董事人数符合法律法规及《公 司章程》等有关规定，决议合法、有效。经与会董事认真审议本次会议议案并表 决，形成本次董事会决议如下： 一、审议通过《2025 年半年度报告及摘要》的议案 董事会认为公司 2025 年半年报报告全文及摘要的编制程序符合法律、行政 法规、中国证监会的规定,报告内容真实、准确、完整的反映了公司的实际情况, 不存在任何虚假记载、误导性陈述或者重大遗漏。因此同意该议案。 表决结果：同 ...

Core Viewpoint - The company reported a decline in operating revenue for the first half of 2025, while net profit showed an increase, indicating mixed financial performance [1] Financial Performance - Operating revenue for the first half of 2025 was 436 million yuan, representing a year-on-year decrease of 9.49% [1] - Net profit for the same period was 1.4189 million yuan, reflecting a year-on-year increase of 11.38% [1]

Financial Performance - The company's operating revenue for the first half of 2025 was ¥436,153,289.26, representing a decrease of 9.49% compared to ¥481,903,187.33 in the same period last year[18]. - The net profit attributable to shareholders of the listed company increased by 11.38% to ¥1,418,926.14, up from ¥1,273,940.73 in the previous year[18]. - The net profit after deducting non-recurring gains and losses improved significantly, showing a reduction in losses to ¥-3,279,782.89 from ¥-6,658,854.46, a 50.75% improvement[18]. - The company's operating revenue for the reporting period was ¥436,153,289.26, a decrease of 9.49% compared to ¥481,903,187.33 in the same period last year[43]. - Total revenue for the reporting period was ¥436,153,289.26, a decrease of 9.49% compared to ¥481,903,187.33 in the same period last year[46]. - Operating profit for the first half of 2025 was ¥4,630,620.51, compared to ¥6,784,725.29 in the first half of 2024, indicating a decline of 31.7%[154]. - Net profit for the first half of 2025 was ¥3,102,408.00, down from ¥4,013,732.20 in the previous year, representing a decrease of 22.6%[154]. - The company reported a total comprehensive income of 1,273,940.73 yuan for the current period, indicating a positive financial performance[168]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,234,597,303.14, a decrease of 1.87% from ¥1,258,163,006.60 at the end of the previous year[18]. - The company's total assets decreased from CNY 1,258,163,006.60 to CNY 1,234,597,303.14, reflecting a decline of approximately 1.9%[146]. - Total liabilities amounted to ¥1,114,278,784.94, slightly down from ¥1,140,864,832.23 in the previous period[148]. - The total liabilities increased from CNY 1,258,163,006.60 to CNY 1,234,597,303.14, reflecting a decrease of about 1.9%[147]. - The company's total liabilities were reported at 472,947,400.00 yuan, which is essential for assessing its financial leverage and risk profile[166]. Cash Flow - The net cash flow from operating activities decreased by 23.56%, indicating potential challenges in cash generation[18]. - The net cash flow from operating activities was ¥29,850,559.58, down 23.56% from ¥39,051,358.84 year-on-year[44]. - Cash flow from operating activities for the first half of 2025 was 29,850,559.58, down from 39,051,358.84 in 2024, reflecting a decrease in cash generation[159]. - The total cash inflow from operating activities was 413,326,519.84 in 2025, compared to 489,286,494.14 in 2024, indicating a decline in cash receipts[159]. - The total cash outflow from operating activities was 383,475,960.26 in 2025, down from 450,235,135.30 in 2024, suggesting improved cost management[159]. Operational Strategy - The company plans not to distribute cash dividends or issue bonus shares, indicating a focus on reinvestment[5]. - The company is actively analyzing future risks and response strategies as outlined in the management discussion section of the report[4]. - The company is facing increasing competition in the ophthalmology medical service sector, with a growing number of market players and a saturated traditional business landscape[66]. - To address market competition, the company is implementing a differentiated competition strategy, focusing on enhancing service quality and optimizing market strategies[67]. - The company is committed to enhancing its technical capabilities and business scale, maintaining a leading position in the private ophthalmology industry[25]. Medical Services and Operations - The company operates 14 specialized ophthalmology hospitals and 3 optometry clinics across 10 major cities, establishing a comprehensive diagnostic and treatment service system for all eye diseases[25]. - All hospitals under the company are designated medical insurance institutions, ensuring high accessibility and reliable quality of medical services for patients[26]. - The company has developed a standardized and systematic management model for the operation of ophthalmology specialty hospitals, enhancing brand advantages in key regions[34]. - The company has established a nationwide ophthalmology service network, emphasizing quality eye care services in large and medium-sized cities[27]. - The company has implemented a unified brand management strategy while allowing localized marketing measures to enhance brand image[28]. Research and Development - The company has established a dual-center for eye disease research, enhancing its academic and research capabilities[35]. - Research and development expenses were ¥1,250,004.00, showing a slight decrease of 0.23% from ¥1,252,903.94 in the previous year[44]. - The company has invested in advanced ophthalmic diagnostic equipment to improve diagnostic accuracy and treatment effectiveness, enhancing overall service quality[65]. Human Resources - The management team has over 10-15 years of experience, contributing to improved operational efficiency and management systems[37]. - A competitive compensation system and stock incentive plans have been implemented to stabilize the talent pool and encourage proactive engagement[40]. - The company has established a dual-driven talent reserve mechanism, combining internal training and external recruitment to attract and retain skilled medical professionals[69]. - The company is facing human resource risks due to increasing competition for talent, necessitating a robust management structure to maintain service quality[68]. Legal and Compliance - The company is involved in a lawsuit concerning medical device sales with a claim amount of CNY 497.83 million, which has been recognized as a liability[99]. - The company is currently executing a construction contract dispute with a claim amount of CNY 438.69 million, which is still in progress[100]. - The company reported that it does not expect any significant adverse impact from the ongoing litigation cases, as they are not deemed to be major liabilities[101]. - The company emphasizes strict adherence to legal regulations to protect the rights of shareholders and creditors, ensuring accurate and timely information disclosure[83]. Shareholder Information - The total number of common stock shareholders at the end of the reporting period was 43,962[135]. - The largest shareholder, Guangzheng Investment, holds 24.91% of shares, totaling 129,168,708 shares, with no changes during the reporting period[135]. - The total number of restricted shares at the end of the period was 10,249,450 shares, with 93,200 shares released during the reporting period[134]. - The company has a total of 6,779,700 shares under lock-up, with 93,200 shares released and no new shares added during the reporting period[134]. Environmental and Social Responsibility - Commitment to environmental sustainability through compliance with environmental protection regulations and the implementation of wastewater treatment systems[89]. - Active participation in social welfare initiatives, including free medical services and surgeries in impoverished regions[89]. - Launch of the "2025 Shanghai-Yunnan Heart-to-Heart" public welfare campaign to improve grassroots ophthalmic medical services[89].

光正眼科医院集团股份有限公司 光正眼科医院集团股份有限公司 章 程 二〇二五年八月 光正眼科医院集团股份有限公司 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东大会 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第五章 董事会 第一节 董事 第二节 董事会 第六章 经理及其他高级管理人员 第七章 监事会 第一节 监事 第二节 监事会 第八章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第九章 通知与公告 第一节 通知 第二节 公告 第十章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十一章 修改章程 第十二章 附则 光正眼科医院集团股份有限公司 第一章 总 则 1.01 条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为， 根据《公司法》、《证券法》、《上市公司章程指引》（2022 年修订）和其他有关规 定， ...

光正眼科医院集团股份有限公司 2025 年半年度财务报告 光正眼科医院集团股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 光正眼科医院集团股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：光正眼科医院集团股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 60,762,592.34 | 67,688,828.82 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 548,072.10 | 3,242,720.58 | | 应收账款 | 114,553,150.69 | 83,698,426.27 | | 应收款项融资 | | 227,922.41 | | 预付款项 | 11,340,243.19 | 17,031,223.98 | ...

光正眼科医院集团股份有限公司 本次股权转让完成后，鑫天山将成为光正巴州的子公司。本次股权转让不涉 及合并报表范围变化，不会对公司权益产生影响。具体情况请见公司于 2025 年 7 月 17 日发布在巨潮资讯网的公告（公告编号：2025-048）。 近日，上述事项已办理完成工商变更登记备案手续。 特此公告。 光正眼科医院集团股份有限公司 董 事 会 证券代码：002524 证券简称：光正眼科 公告编号：2025-056 光正眼科医院集团股份有限公司 关于向子公司光正巴州转让股权完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 7 月 16 日召开第六届董事会第四次会议，审议通过了《关于向子公司内部股权转让的议 案》，为进一步优化公司内部资源和资产结构，提升管理效率，适应公司战略发 展，公司拟将持有的托克逊县鑫天山燃气有限公司（以下简称"鑫天山"）的全 部股权，转让至全资子公司光正能源（巴州）有限公司（以下简称"光正巴州"）。 1 二〇二五年八月二十二日 ...

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-057 光正眼科医院集团股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 金井集团有限公司(KING JOIN GROUP LIMITED)(以下简称"金井集团")为 公司首次公开发行上市前股东，因该股东为外商投资企业，公司工商登记类型为 "股份有限公司（外商投资、上市）"。2025 年 7 月 9 日，公司收到股东金井 集团的《股东减持结果告知书》，其于 2025 年 6 月 10 日至 6 月 26 日期间通过 二级市场竞价交易的方式累计减持本公司股票 5,085,178 股，占公司总股本 0.98%。至此，该外资股东持有的公司股份全部减持完毕，公司的外商投资企业 性质已与实际情况不符。 公司于 2025 年 8 月 19 日召开第六届董事会第五次会议，审议通过了《关于 工商变更公司类型并修订《公司章程》的议案》,将公司类型由"股份有限公司 （外商投资、上市）"，变更为"股份有限公司（上市）"，具体以公司登记机 关核准的变更 ...

光正眼科医院集团股份有限公司 2025 半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：光正眼科医院集团股份有限公司 金额单位：人民币万元 | 非经营性资 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2025 年初 | 2025 半年度 | 2025 半年度 | 2025 半年度 | 2025 年 6 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 金占用 | | 司的关联关系 | 会计科目 | 占用资金 | 占用累计发 | 占用资金的 | 偿还累计发 | 月 30 日占 | 原因 | | | | | | | 余额 | 生金额（不含 | 利息（如有） | 生额 | 用资金余 | | | | | | | | | 利息） | | | 额 | | | | 现大股东及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 小计 | —— | —— | —— | - | - | - | - | - | —— | ...

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-059 光正眼科医院集团股份有限公司 除上述变更外，公司注册地址、公司网址等均保持不变，上述变更后的事项 自本公告披露之日起正式启用，敬请广大投资者关注，由此带来的不便，敬请谅 解。 特此公告。 关于变更办公地址及联系方式的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）因经营管理需要，公 司主要办公地址、投资者联系方式等发生变化，现就具体变更内容公告如下： | 变更事项 | 变更前 | 变更后 | | --- | --- | --- | | 办公地址 | 新疆维吾尔自治区乌鲁木齐经 | 上海市静安区中兴路 1618 | | | 济技术开发区融合北路 266 号 | 号 7-10 楼 | | 邮政编码 | 830012 | 200070 | | 投资者联系电话 | 0991-3766551 | 021-66290900 | | 电子邮箱 | luoping@xsjyk.com | investor@xsjyk.co ...

Group 1 - The core viewpoint of the article is that Guangzheng Eye Care has provided insights into its business segments, specifically the steel structure engineering and energy operation sectors [1] - The steel structure engineering segment is operated by Guangzheng Steel Structure Co., Ltd. and Guangzheng Construction Group Co., Ltd., focusing on the design, manufacturing, and construction of steel structures, and operates independently without involvement in the clean energy sector [1] - The energy operation segment includes subsidiaries such as Guangzheng Energy (Bazhou) Co., Ltd., Tuokexun County Xintianshan Gas Co., Ltd., and Xinjiang Tianyu Energy Technology Development Co., Ltd., primarily focusing on operation and asset leasing as its core business model [1] Group 2 - The company aims to continuously optimize its business layout and enhance operational efficiency to create long-term value for shareholders [1]